Evaluating paclitaxel hypersensitivity reaction rates with cetirizine premedication at a large academic cancer center.

IntroductionPaclitaxel is associated with hypersensitivity reactions (HSRs) in up to 40% of patients, primarily during the first two lifetime infusions. Standard premedication with diphenhydramine, dexamethasone, and famotidine as recommended by the prescribing information reduces this risk to approximately 10%.1 In July 2023, Dana-Farber Cancer Institute (DFCI) replaced diphenhydramine with cetirizine to minimize sedation and prolonged antihistamine effects.MethodsThis retrospective, IRB-exempt study evaluated HSR rates with cetirizine premedication in adults receiving their first lifetime paclitaxel dose between January 1 and July 31, 2024, using a DFCI paclitaxel titration protocol. Eligible patients received cetirizine, famotidine, and dexamethasone as premedication. The primary endpoint was the HSR rate during the first infusion and was compared to an 8.1% historical HSR rate with diphenhydramine using Fisher's exact test.ResultsAmong 150 patients, the HSR rate with cetirizine was 8.7%, showing no significant difference in HSR rate with diphenhydramine (8.1%, P = 1.00). HSRs were generally milder in the cetirizine group, with less epinephrine use (7.7% vs. 66.7%). Paclitaxel re-challenge was successful in 77% of cetirizine-pretreated patients, and only two patients required allergy referral.ConclusionData from this study suggests paclitaxel HSR rates with cetirizine premedication are not significantly different from HSR rates with diphenhydramine.

• Publication year

  2025

• Venue

  Journal of Oncology Pharmacy Practice

• Publication date

  2025-10-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/10781552251382228PMID 41101302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Understanding and Challenging of Taxane Hypersensitivity

  2024cited by this paper
• A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

  2023cited by this paper
• Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review

  2022cited by this paper
• Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions

  2021cited by this paper
• Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients.

  2020cited by this paper
• Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?

  2017cited by this paper
• Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.

  2015cited by this paper
• A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

  2012cited by this paper

• No citing papers are available for this paper.